Despite its high success rate, the Corona vaccine “Pfizer” faces a problem

Corona virus vaccine announced by “Pfizer” company has exceeded all optimistic expectations after leading pharmaceutical company confirms it will be 90% effective, but nonetheless a major dilemma arises that may spoil the joy of experts with this achievement.

According to Pfizer, the vaccine should be stored at -70 degrees Celsius, which is the temperature usually recorded in Antarctic winter, when most refrigerators in most hospitals around the world reach -20 degrees Celsius.

The availability of the vaccine will also depend on the ability to produce the vaccine in large quantities, to store it under favorable conditions, and sometimes to transport it while keeping it frozen or at low temperature, and to find enough crews to inject it. .

The “New York Times” newspaper reports that the “Pfizer” company manufactures the vaccine at two sites, one in Kalamazoo, Michigan, and the other in Bors, Belgium.

One thousand vials with enough vaccine doses for 5,000 people will be placed in specially designed Pfizer coolers.

It is hoped that the carbon dioxide snow placed inside the boxes will keep the pollen cool, and those boxes will also be equipped with sensors that will allow company employees to monitor temperatures during deliveries.

According to the newspaper, hospitals and pharmacies will need to find ways to store doses until they are needed, through the use of ultra-cold freezers, which may not be available in all parts of the world.

The vaccine may remain valid for use in conventional freezers for up to 5 days, or 15 days in the event that special Pfizer-approved refrigerators are used, as long as the dry ice is replenished and the boxes are not opened any further. twice a day.

But the very low temperatures that require storage of the vaccine can complicate matters in rural areas and other countries that lack the infrastructure and the necessary equipment and devices for storage for long periods of time.

Thus, the newspaper believes that health authorities around the world must develop clear vaccination plans that will increase the number of people who can receive the vaccine before it expires.

“The New York Times” expects about 12.5 million Americans to be vaccinated by the end of the year, meaning Pfizer is preparing to supply the US market with only about 25 million doses this year.

Vaccines should be shipped to those the government considers most in need, as healthcare workers and people living in nursing homes are likely to top this list.